Suven Life Sciences secures product patent in Singapore

18 Oct 2017 Evaluate

Suven Life Sciences has secured one product patent from Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2033.

The granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

134.10 -9.20 (-6.42%)
21-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.10
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 875.10
Lupin 2140.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×